Page last updated: 2024-08-25

oxazolidin-2-one and Hyperlipoproteinemia Type II

oxazolidin-2-one has been researched along with Hyperlipoproteinemia Type II in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	5 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ezzahti, M; Mulder, MT; Roeters van Lennep, JE; Sijbrands, EJ	1
Berthold, HK; Gouni-Berthold, I	1
Blom, DJ; Raal, FJ	1
Al-Saady, N; Bergeron, J; Besseling, J; Fable, J; Hovingh, GK; Hunter, J; Johnson-Levonas, AO; Kastelein, JJ; Koeijvoets, M; Langslet, G; Mitchel, Y; Sapre, A; Shah, S	1
Arai, H; Blaustein, RO; Daida, H; Ikewaki, K; Johnson-Levonas, AO; Kakikawa, T; Maeda, Y; Nakagomi, M; Numaguchi, H; Shirakawa, M; Teramoto, T; Vaidya, S	1

Reviews

2 review(s) available for oxazolidin-2-one and Hyperlipoproteinemia Type II

Article	Year
Familial hypercholesterolaemia: new treatment options. The Netherlands journal of medicine, 2013, Volume: 71, Issue:5 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Benzimidazoles; Humans; Hyperlipoproteinemia Type II; Oligonucleotides; Oxazolidinones	2013
Familial hypercholesterolemia: etiology, diagnosis and new treatment options. Current pharmaceutical design, 2014, Volume: 20, Issue:40 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Benzimidazoles; Benzodiazepines; Humans; Hyperlipoproteinemia Type II; Oligonucleotides; Oxazolidinones	2014

Trials

2 trial(s) available for oxazolidin-2-one and Hyperlipoproteinemia Type II

Article	Year
Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet (London, England), 2015, May-30, Volume: 385, Issue:9983 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, LDL; Double-Blind Method; Female; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Middle Aged; Oxazolidinones; Treatment Outcome; Young Adult	2015
Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with heterozygous familial hypercholesterolemia. Atherosclerosis, 2016, Volume: 249 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Homozygote; Humans; Hyperlipoproteinemia Type II; Japan; Male; Middle Aged; Oxazolidinones; Patient Safety; Time Factors; Treatment Outcome; Young Adult	2016

Article

Year

Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study.

Lancet (London, England), 2015, May-30, Volume: 385, Issue:9983

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, LDL; Double-Blind Method; Female; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Middle Aged; Oxazolidinones; Treatment Outcome; Young Adult

2015

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with heterozygous familial hypercholesterolemia.

Atherosclerosis, 2016, Volume: 249

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Homozygote; Humans; Hyperlipoproteinemia Type II; Japan; Male; Middle Aged; Oxazolidinones; Patient Safety; Time Factors; Treatment Outcome; Young Adult

2016

Other Studies

1 other study(ies) available for oxazolidin-2-one and Hyperlipoproteinemia Type II

Article	Year
Anacetrapib in familial hypercholesterolaemia: pros and cons. Lancet (London, England), 2015, May-30, Volume: 385, Issue:9983 Topics: Anticholesteremic Agents; Female; Humans; Hyperlipoproteinemia Type II; Male; Oxazolidinones	2015